SOTIO Initiates First-In-Human Clinical Trial with IL-15 Superagonist SO-C101
SOTIO and Cytune Pharma, members of the PPF Group, announce the first dosing of cancer patients with SO-C101, a superagonist fusion protein of interleukin IL-15. The phase I/Ib study…
Read More...
Read More...
